Bio Pharma R&D Stays Strong Despite Economics
05/04/2010
PhRMA-member companies alone spent an estimated $45.8 billion on pharmaceutical R&D last year, according to the survey. The Burrill & Company analysis shows that non-PhRMA pharmaceutical research companies in the United States spent an estimated $19.5 billion on R&D in 2009.
While companies have been forced to make difficult business decisions, research spending as a percentage of sales remained high in 2009. Over the past nine years, America's pharmaceutical research companies have consistently invested around 18 percent of domestic sales on R&D activities.
"America's biopharmaceutical research sector takes great pride in its global leadership in the development of new life-saving treatments and cures," said PhRMA President and CEO Billy Tauzin.
Most Read
-
-
What’s Driving Record Industrial Real Estate Demand
Q1 2021
-
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Q3 2020
-
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2020
-
Pandemic Fuels Data Center Growth
Q1 2021
-
Trends in Office and Industrial Parks
Q4 2020
-
35th Annual Survey of Corporate Executives Commentary: Change in Site Selection Priorities and Plans Over the Short and Long Term
Q1 2021